Subject
Physiology (medical),Neurology (clinical),Neurology,Pulmonary and Respiratory Medicine
Reference25 articles.
1. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial;Taranto-Montemurro;Am J Respir Crit Care Med,2019
2. Reboxetine plus oxybutynin for OSA treatment: a 1-week, randomized, placebo-controlled, double-blind crossover trial;Perger;Chest,2022
3. The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial;Lim;J Physiol,2021
4. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA;Rosenberg;J Clin Sleep Med,2022
5. A single dose of noradrenergic/serotonergic reuptake inhibitors combined with an antimuscarinic does not improve obstructive sleep apnoea severity;Thomson;Phys Rep,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献